Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

A Bivalent Adenovirus-Vectored Vaccine Induces a Robust Humoral Response, but Does Not Protect Cynomolgus Macaques Against a Lethal Challenge With Sudan Virus.

van Tol S. et al, (2024), J Infect Dis, 230, 1083 - 1092

Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model

O’Donnell KL. et al, (2024), International Journal of Molecular Sciences, 25

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.

Flaxman A. et al, (2024), PLoS Pathog, 20

Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.

Bissett C. et al, (2024), NPJ Vaccines, 9

Translational Science at the Undergraduate Level: Awakening Talents to Overcome the Valley of Death – Viewpoint Showing a Success Case (Preprint)

Ferreira Jr RS. et al, (2024)

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

Costa Clemens SA. et al, (2024), Lancet Microbe

Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.

Drury RE. et al, (2024), Nat Commun, 15

CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.

Neale I. et al, (2023), mBio, 14

Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols.

Waerlop G. et al, (2023), J Immunol Methods, 523

Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.

Mitsi E. et al, (2023), Nat Commun, 14

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.

Ni T. et al, (2023), iScience, 26

Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.

Port JR. et al, (2023), Nat Commun, 14

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.

Ramasamy MN. et al, (2023), Lancet Microbe

Generation and Characterisation of Monoclonal Antibodies against Nairobi Sheep Disease Virus Nucleoprotein.

Maze EA. et al, (2023), Viruses, 15

The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.

Dzau V. et al, (2023), Lancet

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.

Kelly E. et al, (2023), J Infect, 87, 230 - 241

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.

Hornsby H. et al, (2023), Nat Commun, 14

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.

Costa Clemens SA. et al, (2023), Hum Vaccin Immunother, 19

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.

Liu X. et al, (2023), J Infect, 87, 18 - 26

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.

Barnes E. et al, (2023), Nat Med, 29, 1760 - 1774

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?